Trading-Stocks.de

Healthcare | Health Care Plans | USA
CVS Health shares fall after lower-than-expected revenue

...

CVS reported a loss of $419.0 million, or 37 cents per share, after net income of $3.3 billion, or $3.22 per share, the previous year. The loss includes a $2.2 billion goodwill impairment related to the long-term care business, which faced challenges including lower occupancy rates at skilled nursing facilities and the bankruptcies caused by the failing health of customers at these facilities. Adjusted EPS was $2.14, ahead of the $2.09 per share FactSet consensus. Revenue of $54.4 billion was up from $48.4 billion last year but missed the $54.6 billion FactSet expectation. Pharmacy services revenue of $34.9 million also missed FactSet's consensus for $46.4 billion, and the retail and long-term care segment revenue totaling $22.0 billion was below the FactSet expectation for $28.8 billion. 

...

https://www.marketwatch.com/story/cvs-he...yptr=yahoo

CVS runde 8% im minus...

Nach FastGraphs ist CVS sehr sehr günsitg aktuell.

Hier mal ein netter Artikel. Bin gespannt wie das weitergeht!

https://www.cnbc.com/2019/03/20/cvs-has-...tates.html

CVS beats all around and ups expectations for the year

Earnings power from a major acquisition helped push profit at CVS Health up 42% in the first quarter and the company raised its 2019 forecast after it had started the year with a more pessimistic outlook.

CVS now expects adjusted earnings this year to range from $6.75 to $6.90 per share. That's up from an initial forecast the company made in February for earnings of $6.68 to $6.88 per share, an outlook that fell well below Wall Street expectations.

Analysts now expect earnings of $6.79 per share, according to FactSet.

...

https://finance.yahoo.com/news/cvs-healt...15351.html

So, habe meine Position in CVS aufgestockt. Mir gefällt der Healthcare-Bereich, er ist azyklisch. Mir gefällt die Strategie von CVS, raus aus der Pharma-(Groß)händler-Ecke (mit Margendruck und dem Damokles-Schwert Amazon), hin zu einem integrierten Healthcare-Service-Provider. Die Akquisitionen (Aetna) scheinen zu klappen.

Die Dividende ist erstmal eingefroren, aber das wird schon noch wieder, wenn die Schulden weiter getilgt sind. Bis dahin habe ich Zeit.

Aktuelle Analyse:

https://seekingalpha.com/article/4264634...trong-buys

Zitat:CVS Health  Q2 results: 
Revenues: $63,431M (+35.2%); Products: $45,531M (-0.3%); Premiums: $15,791M; Services: $1,816M; Net investment income: $293M (+36.9%).
Pharmacy Services $34,842M (+4.8%); Retail/LTC: $21,447M (+3.7%); Health Care Benefits: $17,403M; Other: $161M (-23.3%).

Net Income: $1,931M (+175.4%)
EPS: $1.49 (+159.1%)
Non-GAAP Net Income: $2,462M (+43.1%)
Non-GAAP EPS: $1.89 (+11.8%)
CF Ops: $7,286M (+37.8%).
[b]2019 Guidance[/b]: GAAP EPS: $4.93 - 5.04 from $4.90 - 5.05; Non-GAAP EPS: $6.89 - 7.00 from $6.75 - 6.90; CF Ops: $10.1B - 10.6B from $9.8B - 10.3B.
[b]Q3 Guidance[/b]: GAAP EPS: $1.16 - 1.20; Non-GAAP EPS: $1.75 - 1.79.
Shares are up 6% premarket.

Sieht gut aus.

CVS Health (CVS) Surpasses Q4 Earnings and Revenue Estimates

CVS Health (CVS) came out with quarterly earnings of $1.73 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $2.14 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 2.98%. A quarter ago, it was expected that this drugstore chain and pharmacy benefits manager would post earnings of $1.77 per share when it actually produced earnings of $1.84, delivering a surprise of 3.95%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

CVS Health, which belongs to the Zacks Retail - Pharmacies and Drug Stores industry, posted revenues of $66.89 billion for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 4.16%. This compares to year-ago revenues of $54.42 billion.


...

https://finance.yahoo.com/news/cvs-healt...12864.html

Halbierung der Erträge wegen der hohen Verschuldung, das drückt den Kurs. Die langfristigen Verbindlichkeiten werden abgebaut, aber insgesamt wird die Verschuldung nicht wirklich abgebaut. Sieht nach einem zähen Kampf aus, aber noch macht das Unternehmen Gewinne. Erwarte weiteren Rücklauf auf Vor-Corona-Niveau. 

Quelle: Macrotrends.net